Press Release

Hospitals for Humanity unveils Efe Ejeba as its 1K1M Fundraising Ambassador for its Paediatric Cardiothoracic Surgery Initiative

1 Mins read

Hospitals for Humanity unveils its Fundraising Ambassador- Efe Ejeba (Winner BBN 2017) for its 1K1M fundraising campaign. Launched earlier this year, the 1K1M fundraising campaign is an effort to get one million people donate at least 1,000 Naira (or its currency equivalent) to its Paediatric Cardiothoracic Surgery Initiative which brings (over 90%) free open heart surgeries to children born with congenital heart defects in Nigeria.

With a ‘revolving-live- list’ of one thousand children per time, two hundred of who urgently need surgery, Hospitals for Humanity has set a fundraising goal of NGN1 Billion for its Fundraising Campaign to provide open heart surgeries to children in need in Nigeria. Donations will be used to provide open heart surgeries via funding specifics like but not limited to:

  • Surgical consumables & supplies
  • Lab (Pre, Peri & Post operation)
  • X-rays (Pre, Peri & Post op)
  • Cardiac cauterization
  • Echocardiograms (Pre, Peri & Post Op)
  • 10 days of hospitalization in the Paediatric Intensive Care Unit (PICU) & Step down unit
  • 1 year follow up care.
  • 1 year medication.

Dr. Segun Ajayi (Founder/CEO Hospitals for Humanity) & Efe Ejeba (1K1M Fundraising Ambassador/ Winner BBN 2017)

Related posts
Press Release

Meet the 2024 Solutions Journalism Africa Mentors

1 Mins read
Since the commencement of the Solutions Journalism Africa Initiative (SJAI) in Nigeria in late 2021, newsrooms and journalists have understood the importance…
Press Release

Gavi and UNICEF welcome approval of new oral cholera vaccine

3 Mins read
Gavi, the Vaccine Alliance and UNICEF welcome the news that a new oral cholera vaccine (OCV), Euvichol-S, has now received WHO prequalification…
Press Release

Participants in Nigeria vaccinated in first-ever Phase 2 Lassa fever vaccine clinical trial, sponsored by IAVI

7 Mins read
The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI’s single dose Lassa fever vaccine candidate Key takeaways • Participants…

Leave a Reply

Your email address will not be published. Required fields are marked *